 |
18 Diseases |  |
0 Trials |
|
0 Trials |  |
25 News |  |
- || PDA-002 / Celularity
Clinical, P2a data, Journal: Phase 2a Randomized Controlled Study Investigating the Safety and Efficacy of PDA-002 in Diabetic Peripheral Neuropathy. (Pubmed Central) - Feb 15, 2022
Mesenchymal stem cells represent a novel mechanism for treating diabetic neuropathy and are well tolerated. Preliminary results highlight the need of further investigation of PDA-001 as a disease modifying agent for treatment of DPN.
- ||||| cenplacel (PDA-002) / Celularity
Trial completion date, Trial termination, Trial primary completion date: Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease (clinicaltrials.gov) - Feb 19, 2019
P2, N=159, Terminated, Sponsor: Celularity Incorporated
Preliminary results highlight the need of further investigation of PDA-001 as a disease modifying agent for treatment of DPN. Trial completion date: Nov 2018 --> Feb 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2018 --> Feb 2018; Business decision with all subjects completing at least 1 year follow-up
- | cenplacel (PDA-002) / Celularity
Trial completion, Trial completion date: A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Feb 5, 2018
P2, N=26, Completed, Sponsor: Celgene
Trial completion date: Nov 2018 --> Feb 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2018 --> Feb 2018; Business decision with all subjects completing at least 1 year follow-up Active, not recruiting --> Completed | Trial completion date: Nov 2017 --> Oct 2017
- cenplacel (PDA-002) / Celularity
Trial primary completion date: A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy (clinicaltrials.gov) - May 24, 2017
P2, N=26, Active, not recruiting, Sponsor: Celgene
Active, not recruiting --> Completed | Trial completion date: Nov 2017 --> Oct 2017 Trial primary completion date: Dec 2017 --> Mar 2017
- || cenplacel (PDA-002) / Celularity
Trial primary completion date: Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease (clinicaltrials.gov) - May 11, 2017
P2, N=182, Active, not recruiting, Sponsor: Celgene
Trial primary completion date: Dec 2017 --> Mar 2017 Trial primary completion date: Jul 2018 --> Nov 2018
- ||| cenplacel (PDA-002) / Celularity
Enrollment closed, Enrollment change: Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease (clinicaltrials.gov) - Apr 4, 2017
P2, N=182, Active, not recruiting, Sponsor: Celgene
Trial primary completion date: Jul 2018 --> Nov 2018 Recruiting --> Active, not recruiting | N=133 --> 182
- | cenplacel (PDA-002) / Celularity
Trial completion: Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU (clinicaltrials.gov) - Feb 24, 2017
P1, N=15, Completed, Sponsor: Celgene
Recruiting --> Active, not recruiting | N=133 --> 182 Active, not recruiting --> Completed
- | cenplacel (PDA-002) / Celularity
Enrollment closed: A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Oct 4, 2016
P2, N=26, Active, not recruiting, Sponsor: Celgene Corporation
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- cenplacel (PDA-002) / Celularity
Trial primary completion date: Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU (clinicaltrials.gov) - Jul 23, 2016
P1, N=15, Active, not recruiting, Sponsor: Celgene Corporation
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2016 --> Sep 2016
- cenplacel (PDA-002) / Celularity
Trial primary completion date: A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Apr 26, 2016
P2, N=24, Recruiting, Sponsor: Celgene Corporation
Trial primary completion date: Mar 2016 --> Sep 2016 Trial primary completion date: May 2017 --> Dec 2017
- cenplacel (PDA-002) / Celularity
Enrollment change, Trial withdrawal, Trial primary completion date: Safety, Hemodynamic Effects and Efficacy of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease (clinicaltrials.gov) - Apr 21, 2016
P2, N=0, Withdrawn, Sponsor: Celgene Corporation
Trial primary completion date: May 2017 --> Dec 2017 N=24 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Jan 2017 --> Sep 2017
- || cenplacel (PDA-002) / Celularity
Trial primary completion date: Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease (clinicaltrials.gov) - Apr 7, 2016
P2, N=133, Recruiting, Sponsor: Celgene Corporation
N=24 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Jan 2017 --> Sep 2017 Trial primary completion date: Oct 2016 --> Jul 2018
- | cenplacel (PDA-002) / Celularity
Enrollment closed: Safety, Hemodynamic Effects and Efficacy of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease (clinicaltrials.gov) - Jan 5, 2016
P2, N=24, Active, not recruiting, Sponsor: Celgene Corporation
Trial primary completion date: Oct 2016 --> Jul 2018 Recruiting --> Active, not recruiting
- | cenplacel (PDA-002) / Celularity
Enrollment open: A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Nov 27, 2015
P2, N=24, Recruiting, Sponsor: Celgene Corporation
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- cenplacel (PDA-002) / Celularity
Enrollment change: Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU (clinicaltrials.gov) - Oct 26, 2015
P1, N=15, Active, not recruiting, Sponsor: Celgene Corporation
Not yet recruiting --> Recruiting N=24 --> 15
- | cenplacel (PDA-002) / Celularity
New P2 trial: A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Sep 17, 2015
P2, N=24, Not yet recruiting, Sponsor: Celgene Corporation
- | cenplacel (PDA-002) / Celularity
Enrollment open: Safety, Hemodynamic Effects and Efficacy of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease (clinicaltrials.gov) - Jul 2, 2015
P2, N=24, Recruiting, Sponsor: Celgene Corporation
N=24 --> 15 Not yet recruiting --> Recruiting
- | cenplacel (PDA-002) / Celularity
New P2 trial: Safety, Hemodynamic Effects and Efficacy of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease (clinicaltrials.gov) - Jun 3, 2015
P2, N=24, Not yet recruiting, Sponsor: Celgene Corporation
- cenplacel (PDA-002) / Celularity
Enrollment closed: Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU (clinicaltrials.gov) - Dec 17, 2014
P1, N=24, Active, not recruiting, Sponsor: Celgene Corporation
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| cenplacel (PDA-002) / Celularity
Enrollment open: Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease (clinicaltrials.gov) - Dec 13, 2014
P2, N=133, Recruiting, Sponsor: Celgene Corporation
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| cenplacel (PDA-002) / Celularity
New P2 trial: Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease (clinicaltrials.gov) - Oct 17, 2014
P2, N=133, Not yet recruiting, Sponsor: Celgene Corporation
- | cenplacel (PDA-002) / Celularity
New P1 trial: Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU (clinicaltrials.gov) - May 19, 2013
P1, N=24, Recruiting, Sponsor: Celgene Corporation